Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter

Launched by JAN CALISSENDORFF · Apr 19, 2021

Keywords

ClinConnect Summary

This clinical trial is studying whether a special solution called Lugol's solution can help reduce complications during thyroid surgery for people with hyperthyroidism, specifically those with Graves' disease or toxic nodular goiter. The main goal is to see if using this solution before surgery can lower the risks of having problems such as damage to the parathyroid glands or the laryngeal nerve, which can affect voice and calcium levels in the body.

To participate in this trial, you should be between the ages of 18 and 75 and have hyperthyroidism that requires surgery. You will need to give your written consent to join the study. However, certain health conditions, like heart problems or severe infections, may disqualify you from participating. If you decide to join, you can expect close monitoring throughout the study and support from the medical team to ensure your safety. This trial is currently recruiting participants, and your involvement could help improve surgical outcomes for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Hyperthyroidism accepted for thyroidectomy due to toxic nodular goiter with free T4 \<30 pmol/L or Graves' disease
• • Signed informed consent
• Exclusion Criteria:
• • Unstable coronary artery disease
• • Previous thyroid surgery
• • Congestive heart failure
• • Renal insufficiency
• • Hepatic failure
• • Current infection
• • Treatment with steroids or anticoagulants
• • Thyroid associated orbitopathy CAS \> 2
• • Diabetes mellitus type 1
• • Active cancer
• • Severe psychiatric illness
• • Amiodarone treatment
• • Pregnancy
• • Breast feeding
• • Women of child bearing potential not using contraceptive
• • Inability to comprehend the meaning of the study
• • Iodine hypersensitivity